These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20227031)

  • 1. Adverse effects of drugs in the treatment of viral hepatitis.
    Negro F
    Best Pract Res Clin Gastroenterol; 2010 Apr; 24(2):183-92. PubMed ID: 20227031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of chronic viral hepatitis].
    Pedersen C; Pedersen CR
    Ugeskr Laeger; 2008 Jun; 170(24):2137-40. PubMed ID: 18565297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
    Rockstroh JK; Bhagani S; Benhamou Y; Bruno R; Mauss S; Peters L; Puoti M; Soriano V; Tural C;
    HIV Med; 2008 Feb; 9(2):82-8. PubMed ID: 18257771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin.
    Yalcin K; Degertekin H; Yildiz F; Kilinc N
    J Gastroenterol; 2003; 38(8):796-800. PubMed ID: 14505137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial.
    Villa E; Grottola A; Buttafoco P; Colantoni A; Bagni A; Ferretti I; Cremonini C; Bertani H; Manenti F
    Am J Gastroenterol; 2001 Oct; 96(10):2973-7. PubMed ID: 11693335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic viral hepatitis and chronic kidney disease.
    Chacko EC; Surrun SK; Mubarack Sani TP; Pappachan JM
    Postgrad Med J; 2010 Aug; 86(1018):486-92. PubMed ID: 20709771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural leukocyte interferon alfa for the treatment of chronic viral hepatitis in heart transplant recipients.
    Fagiuoli S; Pevere S; Minniti F; Livi U; Caforio AL; Naccarato R; Chiaramonte M
    Transplantation; 2003 Apr; 75(7):982-6. PubMed ID: 12698084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
    Schaefer M; Schmidt F; Folwaczny C; Lorenz R; Martin G; Schindlbeck N; Heldwein W; Soyka M; Grunze H; Koenig A; Loeschke K
    Hepatology; 2003 Feb; 37(2):443-51. PubMed ID: 12540795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Monitoring patients with chronic hepatitis during and after therapy].
    Colić-Cvrlje V; Mise S
    Acta Med Croatica; 2009 Dec; 63(5):377-83. PubMed ID: 20198895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
    Chehadeh W; Al-Nakib W
    J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hepatitis C--standard therapy].
    Rasenack JW
    Praxis (Bern 1994); 2000 Jun; 89(24):1049-55. PubMed ID: 10902461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events.
    Smith JP
    Pharmacotherapy; 2008 Sep; 28(9):1151-61. PubMed ID: 18752386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of chronic hepatitis B: an overview.
    Esteban R
    Semin Liver Dis; 2002; 22 Suppl 1():1-6. PubMed ID: 12447723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of chronic hepatitis C virus infection: a new era of disease control.
    Teoh NC; Farrell GC
    Intern Med J; 2004 Jun; 34(6):324-37. PubMed ID: 15228394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management and therapy of chronic hepatitis C virus infection in HIV-infected individuals.
    Mauss S
    J HIV Ther; 2007 Mar; 12(1):11-7. PubMed ID: 17589391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribavirin in the treatment of hepatitis C.
    Abonyi ME; Lakatos PL
    Anticancer Res; 2005; 25(2B):1315-20. PubMed ID: 15865084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of HBV- and HCV-induced end stage liver disease.
    Mutimer DJ; Lok A
    Gut; 2012 May; 61 Suppl 1():i59-67. PubMed ID: 22504920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: investigational agents for chronic hepatitis C.
    Thompson AJ; McHutchison JG
    Aliment Pharmacol Ther; 2009 Apr; 29(7):689-705. PubMed ID: 19183149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon alfa-induced adverse effects in patients with a psychiatric diagnosis.
    Pariante CM; Landau S; Carpiniello B;
    N Engl J Med; 2002 Jul; 347(2):148-9. PubMed ID: 12110753
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.